{
    "clinical_study": {
        "@rank": "67176", 
        "arm_group": [
            {
                "arm_group_label": "Phase II: mFOLFIRINOX", 
                "arm_group_type": "Experimental", 
                "description": "Oxaliplatin 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU) 2,400 mg/m^2, Days 2-4, IV over 46 hours"
            }, 
            {
                "arm_group_label": "Phase II: mFOLFIRINOX + PEGPH20", 
                "arm_group_type": "Experimental", 
                "description": "PEGPH20, dose to be decided during Phase I, IV over 15 minutes; Oxaliplatin, 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m^2, Days 2-4, IV over 46 hours"
            }, 
            {
                "arm_group_label": "Phase I", 
                "arm_group_type": "Experimental", 
                "description": "PEGPH20, 3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes; Oxaliplatin, 85 mg/m^2, on Day 2, IV over 2 hours; Leucovorin, 400 mg/m^2, on Day 2, IV over 2 hours; Irinotecan, 180 mg/m^2, on Day 2, IV over 1.5 hours; 5-fluorouracil (5-FU), 2,400 mg/m^2, Days 2-4, IV over 46 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "Modified FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin) is a common\n      chemotherapy regimen for patients with metastatic pancreatic adenocarcinoma. Investigators\n      want to find out if combining this regimen with another drug, pegylated recombinant human\n      hyaluronidase (PEGPH20), will improve overall patient survival."
        }, 
        "brief_title": "S1313, Phase IB/II Randomized Study of MFOLFIRINOX + PEGPH20 Vs MFOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma", 
        "completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Pancreatic Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": "Adenocarcinoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS\n\n          -  Newly diagnosed, untreated metastatic histologically or cytologically documented\n             pancreatic adenocarcinoma with no known history of brain metastases.\n\n          -  Measurable metastatic disease\n\n          -  No prior treatment with oxaliplatin or irinotecan within 3 years prior to\n             registration. Must not have had prior chemotherapy in metastatic setting. Prior\n             abdominal radiation therapy is not allowed.\n\n        CLINICAL/LABORATORY\n\n          -  Zubrod Performance Status of 0-1\n\n          -  ANC >/= 1,500/uL\n\n          -  Platelets >/= 100,000/uL\n\n          -  Hemoglobin >/= 9 g/dL\n\n          -  Total bilirubin </= institutional upper limit of normal (IULN)\n\n          -  AST </= 2.5 x IULN\n\n          -  ALT </= 2.5 X IULN\n\n          -  Serum albumin >/= 3 g/dL\n\n          -  Serum creatinine </= upper limit of normal (ULN) or calculated creatinine clearance >\n             50 ml/min\n\n          -  INR </= 1.2\n\n          -  Not receiving chronic treatment with systemic steroids or other immuno-suppressive\n             agent\n\n          -  Not have liver disease such as cirrhosis, chronic active hepatitis or chronic\n             persistent hepatitis\n\n          -  Not have active bleeding or a pathological condition that is associated with a high\n             risk of bleeding\n\n          -  Must be on active treatment if known history of HIV\n\n          -  No non-malignant medical illnesses that are uncontrolled or whose control may be\n             jeopardized by the treatment\n\n          -  No other prior malignancy is allowed except for: adequately treated basal cell or\n             squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II\n             cancer from which patient is is complete remission, or any other  cancer from which\n             the patient has been disease free for five years.\n\n          -  Must not be pregnant or nursing\n\n          -  Tumor (paraffin block or slides) available for submission and will to submit blood\n             samples"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "172", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959139", 
            "org_study_id": "S1313", 
            "secondary_id": [
                "NCI-2013-01776", 
                "U10CA032102", 
                "S1313"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Phase II: mFOLFIRINOX + PEGPH20", 
                    "Phase I"
                ], 
                "description": "3 ug/kg on Day 1 and Day 3/4, IV over 15 minutes", 
                "intervention_name": "PEGPH20", 
                "intervention_type": "Drug", 
                "other_name": "Pegylated Recombinant Human Hyaluronidase"
            }, 
            {
                "arm_group_label": [
                    "Phase II: mFOLFIRINOX", 
                    "Phase II: mFOLFIRINOX + PEGPH20", 
                    "Phase I"
                ], 
                "description": "85 mg/m^2, on Day 2, IV over 2 hours", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Eloxatin", 
                    "NSC-266046"
                ]
            }, 
            {
                "arm_group_label": [
                    "Phase II: mFOLFIRINOX", 
                    "Phase II: mFOLFIRINOX + PEGPH20", 
                    "Phase I"
                ], 
                "description": "400 mg/m^2, on Day 2, IV over 2 hours", 
                "intervention_name": "Leucovorin", 
                "intervention_type": "Drug", 
                "other_name": "leucovorin calcium"
            }, 
            {
                "arm_group_label": [
                    "Phase II: mFOLFIRINOX", 
                    "Phase II: mFOLFIRINOX + PEGPH20", 
                    "Phase I"
                ], 
                "description": "180 mg/m^2, on Day 2, IV over 1.5 hours", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CPT-11", 
                    "NSC-616348"
                ]
            }, 
            {
                "arm_group_label": [
                    "Phase II: mFOLFIRINOX", 
                    "Phase II: mFOLFIRINOX + PEGPH20", 
                    "Phase I"
                ], 
                "description": "2,400 mg/m^2, Days 2-4, IV over 46 hours", 
                "intervention_name": "5-fluorouracil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "5-FU", 
                    "Adrucil", 
                    "NSC-19893"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin", 
                "Irinotecan", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rrmanathan@tgen.org", 
                    "last_name": "Ramesh K. Ramanathan", 
                    "phone": "480-323-1350"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85719"
                    }, 
                    "name": "Arizona Cancer Center at University Medical Center North"
                }, 
                "investigator": {
                    "last_name": "Ramesh K. Ramanathan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Emad Elquza", 
                    "phone": "520-626-9008"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "University of Arizona Health Sciences Center"
                }, 
                "investigator": {
                    "last_name": "Emad Elquza", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rrmanathan@tgen.org", 
                    "last_name": "Ramesh K. Ramanathan", 
                    "phone": "480-323-1350"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Ramesh K. Ramanathan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lenz@usc.edu", 
                    "last_name": "Heinz-Josef Lenz", 
                    "phone": "323-865-3967"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "University of Southern California"
                }, 
                "investigator": {
                    "last_name": "Heinz-Josef Lenz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "howard.hochster@yale.edu", 
                    "last_name": "Howard S. Hochster", 
                    "phone": "203-785-5702"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Yale University"
                }, 
                "investigator": {
                    "last_name": "Howard S. Hochster", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "philipp@karmanos.org", 
                    "last_name": "Philip A. Philip", 
                    "phone": "313-576-8746"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Wayne State University-Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Philip A. Philip", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "srh@fhcrc.org", 
                    "last_name": "Sunil R. Hingorani", 
                    "phone": "206-667-6921"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98195"
                    }, 
                    "name": "University of Washington Medical Center"
                }, 
                "investigator": {
                    "last_name": "Sunil R. Hingorani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma", 
        "other_outcome": [
            {
                "description": "Explore correlation of maximum decrease in CA 19-9 levels to maximum decrease in CA 19-9 levels with overall survival, progression-free survival and response.", 
                "measure": "Carbohydrate Antigen (CA) 19-9 Levels", 
                "safety_issue": "No", 
                "time_frame": "Within 2 years of the end of the study"
            }, 
            {
                "measure": "Plasma expression of hyaluronan (HA)", 
                "safety_issue": "No", 
                "time_frame": "Within 2 years of end of study"
            }, 
            {
                "measure": "Tumor expression of HA", 
                "safety_issue": "No", 
                "time_frame": "Within 2 years of end of study"
            }
        ], 
        "overall_contact": {
            "email": "kkaberle@swog.org", 
            "last_name": "Kimberly Kaberle", 
            "phone": "210-614-8808"
        }, 
        "overall_contact_backup": {
            "email": "dsparks@swog.org", 
            "last_name": "Dana Sparks", 
            "phone": "210-614-8808"
        }, 
        "overall_official": {
            "affiliation": "Virginia G. Piper Cancer Center", 
            "last_name": "Ramesh K Ramanathan, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Assess safety of mFOLFIRINOX in combination with PEGPH20 and select the optimal dose of PEGPH20 for the Phase II portion.", 
                "measure": "Phase I: Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Phase II: Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959139"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Objective Tumor Response (confirmed and unconfirmed, complete and partial)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "Tolerability of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "Southwest Oncology Group", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Halozyme Therapeutics", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Southwest Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}